Etanercept

Generic Name
Etanercept
Brand Names
Enbrel, Eticovo, Benepali, Erelzi, Nepexto
Drug Type
Biotech
Chemical Formula
-
CAS Number
185243-69-0
Unique Ingredient Identifier
OP401G7OJC
Background

Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).

Indication

Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.

Associated Conditions
Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
-
Clinical Trials
Related News

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

First Posted Date
2013-01-10
Last Posted Date
2017-07-27
Lead Sponsor
Sanofi
Target Recruit Count
776
Registration Number
NCT01764997
Locations
🇺🇸

Investigational Site Number 840203, Washington, D.C., District of Columbia, United States

🇦🇷

Investigational Site Number 032009, Zarate, Argentina

🇨🇱

Investigational Site Number 152018, Santiago, Chile

and more 254 locations

Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome

First Posted Date
2012-11-21
Last Posted Date
2015-12-02
Lead Sponsor
Haukeland University Hospital
Target Recruit Count
4
Registration Number
NCT01730495
Locations
🇳🇴

Dept. of Oncology and Medical Physics, Haukeland University Hospital Bergen, Norway, Bergen, Norway

Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function

First Posted Date
2012-11-21
Last Posted Date
2017-05-10
Lead Sponsor
Medical University of Warsaw
Target Recruit Count
94
Registration Number
NCT01731457
Locations
🇵🇱

Department of General Surgery and Transplantation, Warsaw, Mazowieckie, Poland

Swiss Dermatology Network of Targeted Therapies (SDNTT)

First Posted Date
2012-10-15
Last Posted Date
2024-11-29
Lead Sponsor
Swiss Dermatology Network for Targeted Therapies
Target Recruit Count
1121
Registration Number
NCT01706692
Locations
🇨🇭

Aarau Cantonal Hospital, Aarau, Switzerland

🇨🇭

Inselspital - Bern University Hospital, Bern, Switzerland

🇨🇭

Basel University Hospital, Basel, Switzerland

and more 3 locations

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

First Posted Date
2012-09-21
Last Posted Date
2022-03-15
Lead Sponsor
Amgen
Target Recruit Count
250
Registration Number
NCT01690299
Locations
🇺🇸

University of California Irvine-Department of Dermatology, Irvine, California, United States

🇺🇸

Florida Academic Dermatology Center, Miami, Florida, United States

🇺🇸

International Dermatology Research, Miami, Florida, United States

and more 79 locations

Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry

First Posted Date
2012-07-20
Last Posted Date
2014-08-05
Lead Sponsor
Pfizer
Target Recruit Count
6393
Registration Number
NCT01646385

Prospective Evaluation of the Radiographic Efficacy of Enbrel

First Posted Date
2012-06-20
Last Posted Date
2019-08-16
Lead Sponsor
Pfizer
Target Recruit Count
1821
Registration Number
NCT01623752

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

First Posted Date
2012-05-07
Last Posted Date
2016-08-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
90
Registration Number
NCT01592292

Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

Phase 4
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Etanercept
Drug: placebo
First Posted Date
2012-04-17
Last Posted Date
2016-07-06
Lead Sponsor
Pfizer
Target Recruit Count
491
Registration Number
NCT01578850
Locations
🇨🇿

PV-Medical s.r.o., Zlin, Czech Republic

🇪🇬

Ain Shams University/Al Demerdash Hospital/Diabetology Unit, Cairo, Egypt

🇪🇬

New University Hospital, Alexandria Clinical Research Center, Alexandria, Al Iskandariyah, Egypt

and more 59 locations

Good EULAR Response In Patients With Early Rheumatoid Arthritis

First Posted Date
2012-03-20
Last Posted Date
2016-11-11
Lead Sponsor
Pfizer
Target Recruit Count
76
Registration Number
NCT01558089
Locations
🇬🇷

G. Papanikolaoy, Thessaloniki, Exochi, Greece

🇬🇷

"Olympion therapeutic center" General Clinic of Patras, Patras, Greece

🇬🇷

424 Military Hospital, Thessaloniki, Thessalonikis, Greece

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy